Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  H. Lane,et al.  The family of polo-like kinases. , 1996, Progress in cell cycle research.

[3]  H. Lane,et al.  Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes , 1996, The Journal of cell biology.

[4]  H. Ackermann,et al.  Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer , 1997, Oncogene.

[5]  D. Longo,et al.  Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. , 1997, Biochemical and biophysical research communications.

[6]  J. Yuan,et al.  Polo-like kinase, a novel marker for cellular proliferation. , 1997, The American journal of pathology.

[7]  D. Glover,et al.  Polo-like kinases: a team that plays throughout mitosis. , 1998, Genes & development.

[8]  J. Bisi,et al.  Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[9]  Pirmin Fessler,et al.  References , 1974 .

[10]  Jürgen Bereiter-Hahn,et al.  Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. , 2002, Journal of the National Cancer Institute.

[11]  S. Loibl,et al.  Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells , 2002, Oncogene.

[12]  R. Kaufmann,et al.  Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease , 2002, Journal of cutaneous pathology.

[13]  Takao Takahashi,et al.  Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers , 2003, Cancer science.

[14]  H. Yoshida,et al.  Distinct regulators for Plk1 activation in starfish meiotic and early embryonic cycles , 2003, The EMBO journal.

[15]  W. Dai,et al.  Polo-like kinases and the microtubule organization center: targets for cancer therapies. , 2003, Progress in cell cycle research.

[16]  Xiaoqi Liu,et al.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  W. Weichert,et al.  Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma , 2004, British Journal of Cancer.

[18]  S. Loening,et al.  Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades , 2004, The Prostate.

[19]  Akira Nakagawara,et al.  Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation* , 2004, Journal of Biological Chemistry.

[20]  W. Weichert,et al.  Polo-like kinase 1 expression is a prognostic factor in human colon cancer. , 2005, World journal of gastroenterology.

[21]  Jun Yoshimatsu,et al.  Polo-like kinases (Plks) and cancer , 2005, Oncogene.

[22]  M. V. Vugt,et al.  Getting in and out of mitosis with Polo-like kinase-1 , 2005, Oncogene.

[23]  Nihal Ahmad,et al.  Silencing of polo‐like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  Wei Dai,et al.  Regulation of cell cycle checkpoints by polo-like kinases , 2005, Oncogene.

[25]  W. Weichert,et al.  Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications , 2005, Virchows Archiv.

[26]  K. Strebhardt,et al.  RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy. , 2005, Current pharmaceutical design.

[27]  D. Ma,et al.  Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells , 2006, Apoptosis.

[28]  Y. S. Kim,et al.  Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. , 2006, International journal of oncology.

[29]  S. Kanaji,et al.  Expression of Polo-Like Kinase 1 (PLK1) Protein Predicts the Survival of Patients with Gastric Carcinoma , 2006, Oncology.

[30]  SaraAntonia Li,et al.  Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. , 2006, Pharmacology & therapeutics.

[31]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[32]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[33]  Xin Xu,et al.  Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma , 2009, International journal of cancer.

[34]  X. Miao,et al.  Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. , 2009, World journal of gastroenterology.

[35]  Wentong Li,et al.  Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma , 2009, Journal of Cancer Research and Clinical Oncology.

[36]  M. Nihal,et al.  Polo-like kinase 1 (Plk1) in non-melanoma skin cancers , 2009, Cell cycle.

[37]  D. Lacombe,et al.  Targeted therapies in the treatment of advanced/metastatic NSCLC. , 2009, European journal of cancer.

[38]  D. Glover,et al.  Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.

[39]  A. Jimeno,et al.  A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[40]  Y. Degenhardt,et al.  Targeting Polo-like Kinase in Cancer Therapy , 2010, Clinical Cancer Research.

[41]  A. Ray,et al.  Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics , 2010, Expert opinion on investigational drugs.

[42]  J. Waldron,et al.  Significance of Plk1 regulation by miR‐100 in human nasopharyngeal cancer , 2009, International journal of cancer.

[43]  N. Ahmad,et al.  Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention , 2010, Pharmaceutical Research.

[44]  Y. Shukla,et al.  Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells. , 2010, Biochemical pharmacology.

[45]  C. Rödel,et al.  Tumorigenesis and Neoplastic Progression Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal Cancer , 2010 .

[46]  R. Gilbert,et al.  Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. , 2010, International journal of radiation oncology, biology, physics.

[47]  C. McInnes,et al.  PLK1 as an oncology target: current status and future potential. , 2011, Drug discovery today.